News & media

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #18.

Office of Drug Control suspends cultivation and manufacture licences of Queensland Medicinal Cannabis Licence Holder Rapid Growth Pty Ltd.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #17.

The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #16.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #15

Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021.

On 2 December 2020, Australia voted at the Commission on Narcotic Drugs (CND) on six recommendations concerning the scheduling of cannabis and cannabis related substances, made by the World Health Organisation (WHO) in January 2019 to the CND.

The ODC is seeking comments on a review of the structure, design and administrative processes relating to medicinal cannabis related permits.

Cost recovery arrangements for cannabis-related manufacture licences and permits commenced on 1 November 2020.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #14.

From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #13.

Changes to fees and charges related to the Medicinal Cannabis Scheme under the Narcotic Drugs Act 1967 commenced on 15 July 2020.

Joint media release - Department of Health (ODC) and Australian Border Force.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #12.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #11.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #10.

Submissions in response to the Office of Drug Control's (ODCs) Consultation on Single Licence Model close COB Monday 3 February 2020.

The Office of Drug Control is implementing the 26 recommendations from the Report on the Review of the Narcotic Drugs Act 1967.

Report on the Review into the 2016 medicinal cannabis amendments to the Narcotic Drugs Act 1967 was tabled in Parliament on Thursday 5 September 2019.

The Australian Government will boost the nation's medicinal cannabis industry by prioritising projects that have been granted Major Project Status (MPS) and ultimately driving economic growth.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #9.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #8.

A clarification of the processing rules around the timing of a medicinal cannabis licence and narcotics manufacturing licences.